Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ABC Sees Double Opportunity For Wholesalers In Biosimilars

Executive Summary

AmerisourceBergen is anticipating that the establishment of an FDA approval pathway for biosimilars under health care reform will have a real upside for drug wholesalers

You may also be interested in...

Sanofi-Aventis' 2010 Guidance Remains Unchanged; Q1 Sales Up 3.9 %

The onset of Lovenox generics could be a near-term reality in the U.S., though timing remains uncertain.

Hospira Halts Shipment Of Two Drugs After FDA Warning Letter

Voluntary hold on Propofol, Liposyn will negatively impact 2010 sales, though acquisition of Orchid will help make up the difference.

Patent Round-Up: Sanofi Settles Eloxatin Suits; Lilly Continues Gemzar Fight

Sanofi-Aventis reduces Eloxatin competition: Sanofi-Aventis settled Eloxatin (oxaliplatin) patent infringement suits against Teva, Sandoz and Fresenius Kabi. Under the terms of the settlement the companies will stop selling their generic versions of the colon cancer drug on June 30 and resume marketing under a license on Aug. 9, 2012. The other terms of the settlement are confidential. Eloxatin's compound patent has expired but other patents cover the drug through 2016. As a result of generic competition, Sanofi's U.S. sales of Eloxatin fell from $1.4 billion in 2008 to $930 million in 2009. Hospira, Sun and Sun's U.S. subsidiary Caraco also market generic versions of Eloxatin. Sanofi has pending suits against MN Pharmaceuticals, Mayne Pharma and Actavis

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts